The Spatial Genomics & Transcriptomics Market is projected to reach $3.23 billion by 2031 at a CAGR of 27.8% from 2024 to 2031. Spatial genomics aims to assess the genomic information of individual cells within their native tissue environment. Understanding the association between cells and their specific locations within tissue is crucial for comprehending normal development and disease pathology. A cutting-edge technique within spatial genomics is spatial transcriptomics, a molecular profiling method enabling researchers to quantify gene activity across a tissue sample and pinpoint where this activity is taking place. Spatial genomics applications extend beyond the cellular or tissue level, allowing for the analysis of subcellular transcriptional dynamics. This approach effectively addresses challenges encountered by traditional technologies like single-cell sequencing, offering a clearer perspective of the genome. This clarity proves valuable in translational and drug research.
The growth of the spatial genomics market is driven by the increasing applications of spatial genomics in drug discovery & development, the growing use of spatial genomics in cancer research, advancements in Next-generation Sequencing (NGS), the increasing use of spatial genomics in biomarker detection, and the rising prevalence of cancer. However, the lack of standardized approaches in genomics and concerns over the security & privacy of genomic data restrain the growth of this market.
Furthermore, the rising adoption of personalized medicines and gene therapies and increasing investments in spatial genomics are expected to generate growth opportunities for the players operating in this market. However, complexities in data analysis and slow technology adoption are major challenges impacting market growth.
Pharmaceutical and biotechnology companies are focusing on research and development, with R&D expenditures increasing globally. For instance, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), global pharmaceutical R&D expenditure is expected to increase to USD 213 billion in 2026 from USD 189 billion in 2022. Spatial genomics has become increasingly important in ensuring precision and accuracy in drug research & development and reducing the time required for research.
Numerous drug discovery processes can benefit from the use of spatial genomics, including drug compound synthesis, screening, delivery, and the development of carrier systems. Spatial transcriptomics allows researchers to visualize biomarkers, spatial interactions, and tumor transcriptomes in their native architecture, enabling them to better identify potential drug targets and resistance mechanisms.
Tumor heterogeneity is a major challenge in oncology drug discovery and development. Identifying new targets and appropriate model systems requires an accurate spatial and molecular disease taxonomy. Advances in spatial genomics are enabling the broad characterization of tumor structure, contextualization of established biomarkers, and de novo identification of interactions. Thus, the increasing applications of spatial genomics in drug discovery & development are boosting the adoption of spatial genomics & transcriptomics products.
In many cases, a single molecular event is inadequate to understand disease pathology. Therefore, there is a growing need to develop multianalyte-based tests. Recent technological advancements in spatial transcriptomics have resulted in the development of multiplexed methods. Multiplex imaging allows researchers to simultaneously visualize multiple targets in a single sample, which is important for studying complex biological systems and can help researchers better understand how different molecules and pathways interact with each other, tissue architecture, and disease progression spatially.
According to Nucleai (U.S.), multiplex imaging is a developing technology that stains many proteins on a single slide while maintaining tissue architecture, which provides significant insights into spatial biology and the complexity of the immune tumor microenvironment (iTME). Present multiplex technologies can map as many as 100 unique protein markers to detect cells and their functional state within a single slide, providing a highly detailed picture of the iTME.
Key players are also launching multiplex imaging platforms for spatial analysis to gain a competitive edge in the market. For instance, in November 2022, Nucleai (U.S.) launched a multiplex imaging spatial analysis solution for drug discovery and development. The platform integrates multiplex imaging with machine learning to increase process speed and data reliability.
Based on the offering, the global spatial genomics & transcriptomics market is segmented into instruments, consumables, and software & services. The large market share of the instruments segment is attributed to the need for higher sensitivity and productivity in drug development procedures, increasing demand for instruments for translation and drug development research, and technological advancement in instruments. Additionally, Key players are introducing advanced instruments to fulfill researchers’ requirements, contributing to the largest share of the segment. For instance, in December 2022, 10x Genomics, Inc. (U.S.) launched the Xenium platform, which can sequence the transcripts of thousands of genes in a high-throughput, non-destructive manner.
Based on type, the global spatial genomics & transcriptomics market is segmented into genomics and transcriptomics. The genomics segment is expected to grow at the highest CAGR during the forecast period. The increasing application areas of spatial genomics to provide insights about tissue arrangements and its efficiency in analyzing cell samples within intact tumor cells are propelling the adoption of spatial genomics.
Based on technology, the global spatial genomics & transcriptomics market is segmented into sequencing based and imaging based. The larger share of this segment is attributed to the ability of imaging-based technology to be applied to archival materials and frozen tissues. Imaging-based technologies mainly consist of in situ hybridization and in situ sequencing. Imaging technologies can be combined with immunohistochemistry to detect the protein/mRNA of interest or the phenotype of cells expressing the target genome; detecting more than one nucleic acid sequence is increasing the demand for these technologies. The key players in this market are focused on introducing ISH-based products. For instance, in May 2023, Spatial Genomics (U.S.) introduced the GenePS system, an automated instrument based on seqFISH technology that has an exceptional capacity to panel over 1,000 genes at high resolution.
Based on application, the global spatial genomics market is segmented into oncology, neurology, and other applications. The oncology segment is expected to grow at the highest CAGR during the forecast period. The increasing prevalence of cancer (malignant tumor) and the development of spatial genomics products for the analysis of various biomarkers, including proteins, circulating tumor cells, exosomes, and cell-free DNA, contributed to the highest CAGR of the segment. For instance, cancer is a major health concern globally and is one of the leading causes of morbidity and mortality across the world. According to GLOBOCAN, the global burden of cancer is expected to increase from 19.3 million cases in 2020 to 24.6 million cases by 2030.
Based on end user, the global spatial genomics & transcriptomics market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and other end users. In 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the market. The rising number of research laboratories, increasing investment in R&D, and rising funding for research laboratories support the largest share of the market. The funding for research laboratories is increasing due to the increasing demand for new drugs and therapies. The NIH funding increased from USD 33 billion in 2015 to USD 42 billion in 2021 for research purposes (Source: Congressional Research Service).
Asia-Pacific is expected to grow at the highest CAGR during the forecast period. The growth of the spatial genomics & transcriptomics market in Asia-Pacific is attributed to rising pharmaceutical R&D spending, growth in biotechnology industries in several countries, the increasing prevalence of chronic and infectious diseases, and the rising number of research laboratories in Asia-Pacific. For instance, in 2022, the R&D spending of BeiGene Ltd. (China), one of the major pharmaceutical companies, increased by 12.4% from 2021.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years. The key players operating in the global spatial genomics & transcriptomics market are NanoString Technologies, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Illumina, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Akoya Biosciences, Inc. (U.S.), Revvity, Inc. (U.S.), S2 Genomics, Inc. (U.S.), Cantata Bio (U.S.), Vizgen Inc. (U.S.), Biospyder Technologies Inc. (U.S.), and Resolve Biosciences GmbH (Germany).
|
Particular |
Details |
|
Number of Pages |
198 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR (2024–2031) |
27.8% |
|
Estimated Market Size (Value) |
$3.23 billion by 2031 |
|
Segments Covered |
By Offering
By Type
By Technology
By Application
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, RoE), Asia-Pacific (China, Japan, India, RoAPAC), Latin America, and Middle East and Africa |
|
Key Companies |
NanoString Technologies, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Illumina, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Akoya Biosciences, Inc. (U.S.), Revvity, Inc. (U.S.), S2 Genomics, Inc. (U.S.), Cantata Bio (U.S.), Vizgen Inc. (U.S.), Biospyder Technologies Inc. (U.S.), and Resolve Biosciences GmbH (Germany). |
The global spatial genomics market covers the study of various spatial genomics & transcriptomics instruments, consumables, software, and services based on technologies like imaging and sequencing to be used in various application areas at the regional and country levels.
The global spatial genomics & transcriptomics market is projected to reach $3.23 billion by 2031 at a CAGR of 27.8% during the forecast period.
Among the types, in 2024, the transcriptomics segment is expected to hold a major market share. The largest market share is attributed to the increasing use of spatial transcriptomics by end users as it provides insights about biological interactions at the cellular level to gain insights into complex tissues, such as tumor microenvironments.
Among the technology, in 2024, the imaging based segment is expected to hold a major market share. The larger share of this segment is attributed to imaging-based technology can be applied to archival materials and frozen tissues. It can be combined with immunohistochemistry to detect the protein/mRNA of interest or the phenotype of cells expressing the target genome, detecting more than one nucleic acid sequence using different labeling methods.
Among the application, in 2024, the oncology segment is expected to hold a major market share. The largest share of this segment is attributed to the increasing prevalence of cancer, the increasing need for new diagnostic and treatment methods for managing cancer, and the launches of cancer programs dedicated to translational research.
The growth of the spatial genomics & transcriptomics market is driven by the increasing applications of spatial genomics in drug discovery & development, the growing use of spatial genomics in cancer research, advancements in Next-generation Sequencing (NGS), the increasing use of spatial genomics in biomarker detection, and the rising prevalence of cancer. Furthermore, the rising adoption of personalized medicines and gene therapies and increasing investments in spatial genomics are expected to generate growth opportunities for the players operating in this market.
The key players operating in the global spatial genomics & transcriptomics market are NanoString Technologies, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Illumina, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Akoya Biosciences, Inc. (U.S.), Revvity, Inc. (U.S.), S2 Genomics, Inc. (U.S.), Cantata Bio (U.S.), Vizgen Inc. (U.S.), Biospyder Technologies Inc. (U.S.), and Resolve Biosciences GmbH (Germany).
The emerging countries in the Asian-Pacific are projected to offer significant growth opportunities for the vendors in this market due to the advancing healthcare infrastructure, increasing research laboratories, and rising research funding in the healthcare & pharmaceutical industry.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Impact Analysis of Market Dynamics
4.2.1.1. Increasing Applications of Spatial Genomics in Drug Discovery & Development Driving Market Growth
4.2.1.2. Lack of Standardization and Concerns Over the Privacy of Genomic Data Limiting the Adoption of Spatial Genomics Products
4.2.1.3. Rising Adoption of Personalized Medicines Generating Growth Opportunities for Market Players
4.2.1.4. Complexities in Data Analysis to Remain a Major Challenge Impacting Market Growth
4.2.2. Factor Analysis
4.3. Technology Trends
4.3.1. Integration of Artificial Intelligence (AI) in Spatial Genomics
4.3.2. Multiplexed Spatial Genomics
4.4. Investment and Funding Scenario
4.5. Pricing Analysis
4.6. Porter’s Five Forces Analysis
4.6.1. Bargaining Power of Buyers
4.6.2. Bargaining Power of Suppliers
4.6.3. Threat of Substitutes
4.6.4. Threat of New Entrants
4.6.5. Degree of Competition
5. Spatial Genomics & Transcriptomics Market Assessment—by Offering
5.1. Overview
5.2. Instruments
5.3. Consumables
5.4. Software & Services
6. Spatial Genomics & Transcriptomics Market Assessment—by Type
6.1. Overview
6.2. Transcriptomics
6.3. Genomics
7. Spatial Genomics & Transcriptomics Market Assessment —by Technology
7.1. Overview
7.2. Imaging Based
7.3. Sequencing Based
8. Spatial Genomics & Transcriptomics Market Assessment —by Application
8.1. Overview
8.2. Oncology
8.3. Neurology
8.4. Other Applications
9. Spatial Genomics & Transcriptomics Market Assessment —by End User
9.1. Overview
9.2. Pharmaceutical & Biotechnology Companies
9.3. Contract Research Organizations
9.4. Other End Users
10. Spatial Genomics & Transcriptomics Market Assessment—by Geography
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia-Pacific
10.5. Latin America
10.6. Middle East & Africa
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis
11.5.1. 10X Genomics, Inc. (U.S.)
11.5.2. NanoString Technologies, Inc. (U.S.)
11.5.3. Akoya Biosciences, Inc. (U.S.)
12. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, Strategic Developments, and SWOT Analysis)
12.1. 10X Genomics, Inc.
12.2. NanoString Technologies, Inc.
12.3. Akoya Biosciences, Inc.
12.4. Illumina, Inc.
12.5. Oxford Nanopore Technologies Plc
12.6. Revvity, Inc.
12.7. S2 Genomics, Inc.
12.8. Cantata Bio
12.9. Vizgen Inc.
12.10. Biospyder Technologies Inc.
12.11. Resolve Biosciences GmbH
(Note: SWOT Analysis of Top 5 Companies is Provided)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Estimated Number of New Cancer Cases, by Type, 2020 Vs. 2030
Table 2 Recent Investments and Funding in The Spatial Genomics & Transcriptomics Market
Table 3 Spatial Genomics & Transcriptomics Instruments: Pricing (USD/Unit)
Table 4 Spatial Genomics & Transcriptomics Consumables: Pricing (USD/Unit)
Table 5 Global Spatial Genomics & Transcriptomics Market, by Offering, 2022-2031 (USD Million)
Table 6 Key Companies Offering Instruments
Table 7 Global Spatial Genomics & Transcriptomics Market for Instruments, by Country/Region, 2022-2031 (USD Million)
Table 8 Key Companies Offering Consumables
Table 9 Global Spatial Genomics & Transcriptomics Market for Consumables, by Country/Region, 2022-2031 (USD Million)
Table 10 Key Companies Offering Software
Table 11 Global Spatial Genomics & Transcriptomics Market for Software & Services, by Country/Region, 2022-2031 (USD Million)
Table 12 Global Spatial Genomics & Transcriptomics Market, by Type, 2022-2031 (USD Million)
Table 13 Global Spatial Transcriptomics Market, by Country/Region, 2022-2031 (USD Million)
Table 14 Spatial Genomics: Key Application Areas
Table 15 Global Spatial Genomics Market, by Country/Region, 2022-2031 (USD Million)
Table 16 Global Spatial Genomics & Transcriptomics Market, by Technology, 2022-2031 (USD Million)
Table 17 Global Imaging Based Spatial Genomics & Transcriptomics Market, by Country/Region, 2022-2031 (USD Million)
Table 18 Global Sequencing Based Spatial Genomics & Transcriptomics Market, by Country/Region, 2022-2031 (USD Million)
Table 19 Global Spatial Genomics & Transcriptomics Market, by Application, 2022-2031 (USD Million)
Table 20 Global Spatial Genomics & Transcriptomics Market for Oncology, by Country/Region, 2022-2031 (USD Million)
Table 21 Global Spatial Genomics & Transcriptomics Market for Neurology, by Country/Region, 2022-2031 (USD Million)
Table 22 Global Spatial Genomics & Transcriptomics Market for Other Applications, by Country/Region, 2022-2031 (USD Million)
Table 23 Global Spatial Genomics & Transcriptomics Market, by End User, 2022-2031 (USD Million)
Table 24 Global Spatial Genomics & Transcriptomics Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022-2031 (USD Million)
Table 25 Global Spatial Genomics & Transcriptomics Market for Contract Research Organizations, by Country/Region, 2022-2031 (USD Million)
Table 26 Global Spatial Genomics & Transcriptomics Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
Table 27 Global Spatial Genomics & Transcriptomics Market, by Country/Region, 2022–2031 (USD Million)
Table 28 North America: Spatial Genomics & Transcriptomics Market, by Country, 2022–2031 (USD Million)
Table 29 North America: Spatial Genomics & Transcriptomics Market, by Offering, 2022–2031 (USD Million)
Table 30 North America: Spatial Genomics & Transcriptomics Market, by Type, 2022–2031 (USD Million)
Table 31 North America: Spatial Genomics & Transcriptomics Market, by Technology, 2022–2031 (USD Million)
Table 32 North America: Spatial Genomics & Transcriptomics Market, by Application, 2022–2031 (USD Million)
Table 33 North America: Spatial Genomics & Transcriptomics Market, by End User, 2022–2031 (USD Million)
Table 34 U.S.: Spatial Genomics & Transcriptomics Market, by Offering, 2022–2031 (USD Million)
Table 35 U.S.: Spatial Genomics & Transcriptomics Market, by Type, 2022–2031 (USD Million)
Table 36 U.S.: Spatial Genomics & Transcriptomics Market, by Technology, 2022–2031 (USD Million)
Table 37 U.S.: Spatial Genomics & Transcriptomics Market, by Application, 2022–2031 (USD Million)
Table 38 U.S.: Spatial Genomics & Transcriptomics Market, by End User, 2022–2031 (USD Million)
Table 39 Canada: Spatial Genomics & Transcriptomics Market, by Offering, 2022–2031 (USD Million)
Table 40 Canada: Spatial Genomics & Transcriptomics Market, by Type, 2022–2031 (USD Million)
Table 41 Canada: Spatial Genomics & Transcriptomics Market, by Technology, 2022–2031 (USD Million)
Table 42 Canada: Spatial Genomics & Transcriptomics Market, by Application, 2022–2031 (USD Million)
Table 43 Canada: Spatial Genomics & Transcriptomics Market, by End User, 2022–2031 (USD Million)
Table 44 Europe: Spatial Genomics & Transcriptomics Market, by Country/Region, 2022–2031 (USD Million)
Table 45 Europe: Spatial Genomics & Transcriptomics Market, by Offering, 2022–2031 (USD Million)
Table 46 Europe: Spatial Genomics & Transcriptomics Market, by Type, 2022–2031 (USD Million)
Table 47 Europe: Spatial Genomics & Transcriptomics Market, by Technology, 2022–2031 (USD Million)
Table 48 Europe: Spatial Genomics & Transcriptomics Market, by Application, 2022–2031 (USD Million)
Table 49 Europe: Spatial Genomics & Transcriptomics Market, by End User, 2022–2031 (USD Million)
Table 50 Germany: Spatial Genomics & Transcriptomics Market, by Offering, 2022–2031 (USD Million)
Table 51 Germany: Spatial Genomics & Transcriptomics Market, by Type, 2022–2031 (USD Million)
Table 52 Germany: Spatial Genomics & Transcriptomics Market, by Technology, 2022–2031 (USD Million)
Table 53 Germany: Spatial Genomics & Transcriptomics Market, by Application, 2022–2031 (USD Million)
Table 54 Germany: Spatial Genomics & Transcriptomics Market, by End User, 2022–2031 (USD Million)
Table 55 France: Spatial Genomics & Transcriptomics Market, by Offering, 2022–2031 (USD Million)
Table 56 France: Spatial Genomics & Transcriptomics Market, by Type, 2022–2031 (USD Million)
Table 57 France: Spatial Genomics & Transcriptomics Market, by Technology, 2022–2031 (USD Million)
Table 58 France: Spatial Genomics & Transcriptomics Market, by Application, 2022–2031 (USD Million)
Table 59 France: Spatial Genomics & Transcriptomics Market, by End User, 2022–2031 (USD Million)
Table 60 U.K.: Spatial Genomics & Transcriptomics Market, by Offering, 2022–2031 (USD Million)
Table 61 U.K.: Spatial Genomics & Transcriptomics Market, by Type, 2022–2031 (USD Million)
Table 62 U.K.: Spatial Genomics & Transcriptomics Market, by Technology, 2022–2031 (USD Million)
Table 63 U.K.: Spatial Genomics & Transcriptomics Market, by Application, 2022–2031 (USD Million)
Table 64 U.K.: Spatial Genomics & Transcriptomics Market, by End User, 2022–2031 (USD Million)
Table 65 Italy: Spatial Genomics & Transcriptomics Market, by Offering, 2022–2031 (USD Million)
Table 66 Italy: Spatial Genomics & Transcriptomics Market, by Type, 2022–2031 (USD Million)
Table 67 Italy: Spatial Genomics & Transcriptomics Market, by Technology, 2022–2031 (USD Million)
Table 68 Italy: Spatial Genomics & Transcriptomics Market, by Application, 2022–2031 (USD Million)
Table 69 Italy: Spatial Genomics & Transcriptomics Market, by End User, 2022–2031 (USD Million)
Table 70 Spain: Spatial Genomics & Transcriptomics Market, by Offering, 2022–2031 (USD Million)
Table 71 Spain: Spatial Genomics & Transcriptomics Market, by Type, 2022–2031 (USD Million)
Table 72 Spain: Spatial Genomics & Transcriptomics Market, by Technology, 2022–2031 (USD Million)
Table 73 Spain: Spatial Genomics & Transcriptomics Market, by Application, 2022–2031 (USD Million)
Table 74 Spain: Spatial Genomics & Transcriptomics Market, by End User, 2022–2031 (USD Million)
Table 75 Rest of Europe: Spatial Genomics & Transcriptomics Market, by Offering, 2022–2031 (USD Million)
Table 76 Rest of Europe: Spatial Genomics & Transcriptomics Market, by Type, 2022–2031 (USD Million)
Table 77 Rest of Europe: Spatial Genomics & Transcriptomics Market, by Technology, 2022–2031 (USD Million)
Table 78 Rest of Europe: Spatial Genomics & Transcriptomics Market, by Application, 2022–2031 (USD Million)
Table 79 Rest of Europe: Spatial Genomics & Transcriptomics Market, by End User, 2022–2031 (USD Million)
Table 80 Asia-Pacific: Spatial Genomics Market, by Country/Region, 2022–2031 (USD Million)
Table 81 Asia-Pacific: Spatial Genomics Market, by Offering, 2022–2031 (USD Million)
Table 82 Asia-Pacific: Spatial Genomics Market, by Type, 2022–2031 (USD Million)
Table 83 Asia-Pacific: Spatial Genomics Market, by Technology, 2022–2031 (USD Million)
Table 84 Asia-Pacific: Spatial Genomics Market, by Application, 2022–2031 (USD Million)
Table 85 Asia-Pacific: Spatial Genomics Market, by End User, 2022–2031 (USD Million)
Table 86 China: Spatial Genomics Market, by Offering, 2022–2031 (USD Million)
Table 87 China: Spatial Genomics Market, by Type, 2022–2031 (USD Million)
Table 88 China: Spatial Genomics Market, by Technology, 2022–2031 (USD Million)
Table 89 China: Spatial Genomics Market, by Application, 2022–2031 (USD Million)
Table 90 China: Spatial Genomics Market, by End User, 2022–2031 (USD Million)
Table 91 Japan: Spatial Genomics Market, by Offering, 2022–2031 (USD Million)
Table 92 Japan: Spatial Genomics Market, by Type, 2022–2031 (USD Million)
Table 93 Japan: Spatial Genomics Market, by Technology, 2022–2031 (USD Million)
Table 94 Japan: Spatial Genomics Market, by Application, 2022–2031 (USD Million)
Table 95 Japan: Spatial Genomics Market, by End User, 2022–2031 (USD Million)
Table 96 India: Spatial Genomics Market, by Offering, 2022–2031 (USD Million)
Table 97 India: Spatial Genomics Market, by Type, 2022–2031 (USD Million)
Table 98 India: Spatial Genomics Market, by Technology, 2022–2031 (USD Million)
Table 99 India: Spatial Genomics Market, by Application, 2022–2031 (USD Million)
Table 100 India: Spatial Genomics Market, by End User, 2022–2031 (USD Million)
Table 101 Rest of Asia-Pacific: Spatial Genomics Market, by Offering, 2022–2031 (USD Million)
Table 102 Rest of Asia-Pacific: Spatial Genomics Market, by Type, 2022–2031 (USD Million)
Table 103 Rest of Asia-Pacific: Spatial Genomics Market, by Technology, 2022–2031 (USD Million)
Table 104 Rest of Asia-Pacific: Spatial Genomics Market, by Application, 2022–2031 (USD Million)
Table 105 Rest of Asia-Pacific: Spatial Genomics Market, by End User, 2022–2031 (USD Million)
Table 106 Latin America: Spatial Genomics Market, by Offering, 2022–2031 (USD Million)
Table 107 Latin America: Spatial Genomics Market, by Type, 2022–2031 (USD Million)
Table 108 Latin America: Spatial Genomics Market, by Technology, 2022–2031 (USD Million)
Table 109 Latin America: Spatial Genomics Market, by Application, 2022–2031 (USD Million)
Table 110 Latin America: Spatial Genomics Market, by End User, 2022–2031 (USD Million)
Table 111 Middle East & Africa: Spatial Genomics Market, by Offering, 2022–2031 (USD Million)
Table 112 Middle East & Africa: Spatial Genomics Market, by Type, 2022–2031 (USD Million)
Table 113 Middle East & Africa: Spatial Genomics Market, by Technology, 2022–2031 (USD Million)
Table 114 Middle East & Africa: Spatial Genomics Market, by Application, 2022–2031 (USD Million)
Table 115 Middle East & Africa: Spatial Genomics Market, by End User, 2022–2031 (USD Million)
Table 116 Recent Developments, by Company, 2020–2023
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Spatial Genomics & Transcriptomics Market, by Offering, 2024 Vs. 2031 (USD Million)
Figure 8 Global Spatial Genomics & Transcriptomics Market, by Type, 2024 Vs. 2031 (USD Million)
Figure 9 Global Spatial Genomics & Transcriptomics Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 10 Global Spatial Genomics & Transcriptomics Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 11 Global Spatial Genomics & Transcriptomics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 12 Spatial Genomics & Transcriptomics Market, by Geography
Figure 13 Impact Analysis of Market Dynamics
Figure 14 Global Pharmaceutical R&D Expenditure, 2012–2026 (USD Billion)
Figure 15 Estimated Number of New Cancer Cases, by Region, 2020 Vs. 2030 (In Thousand)
Figure 16 Global Increase in The Number of Personalized Medicine Approvals, 2008–2020
Figure 17 Porter’s Five Forces Analysis
Figure 18 Global Spatial Genomics & Transcriptomics Market, by Offering, 2024 Vs. 2031 (USD Million)
Figure 19 Global Spatial Genomics & Transcriptomics Market, by Type, 2024 Vs. 2031 (USD Million)
Figure 20 Global Spatial Genomics & Transcriptomics Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 21 Imaging Based Methods: Workflow
Figure 22 Sequencing Based Methods: Workflow
Figure 23 Global Spatial Genomics & Transcriptomics Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 24 Global Spatial Genomics & Transcriptomics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 25 Global Pharmaceutical R&D Spending, 2012–2026 (USD Billion)
Figure 26 Global Spatial Genomics & Transcriptomics Market, by Region, 2024 Vs. 2031 (USD Million)
Figure 27 North America: Spatial Genomics & Transcriptomics Market Snapshot
Figure 28 U.S.: Pharmaceutical R&D Expenditures, 2014-2021 (USD Billion)
Figure 29 Europe: Pharmaceutical R&D Expenditures, 2000-2021 (USD Million)
Figure 30 Europe: Spatial Genomics & Transcriptomics Market Snapshot
Figure 31 Roe: Countries Pharmaceutical R&D Expenditures, 2021 (USD Million)
Figure 32 Asia-Pacific: Spatial Genomics Market Snapshot
Figure 33 Key Growth Strategies Adopted by Leading Players, 2020–2023
Figure 34 Spatial Genomics & Transcriptomics Market: Competitive Benchmarking (Based on Offering)
Figure 35 Spatial Genomics & Transcriptomics Market: Competitive Benchmarking (Based on Geography)
Figure 36 Competitive Dashboard: Spatial Genomics & Transcriptomics Market
Figure 37 Global Spatial Genomics & Transcriptomics Market Share Analysis, by Key Players (2023)
Figure 38 10x Genomics, Inc.: Financial Overview (2022)
Figure 39 NanoString Technologies, Inc.: Financial Overview (2022)
Figure 40 Akoya Biosciences, Inc.: Financial Overview (2022)
Figure 41 Illumina, Inc.: Financial Overview (2022)
Figure 42 Oxford Nanopore Technologies Plc.: Financial Overview (2022)
Figure 43 PerkinElmer, Inc: Financial Overview (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Feb-2024
Published Date: Aug-2017
Published Date: Dec-2023
